ISSN:
0730-2312
Schlagwort(e):
IGF-I
;
non-small cell lung cancer
;
monoclonal antibodies
;
growth
;
receptors
;
Life Sciences
;
Molecular Cell Biology
Quelle:
Wiley InterScience Backfile Collection 1832-2000
Thema:
Biologie
,
Chemie und Pharmazie
,
Medizin
Notizen:
The ability of monoclonal antibody (mAb) αI̊-3 to interact with non-small cell lung cancer (NSCLC) cells was investigated. MAb αI̊-3 inhibited specific binding of 125I-IGF-I and 125I-αI̊-3 to a panel of 8 NSCLC cell lines with high affinity (IC50 = 200 and 50 ng/ml, respectively). 125I-αI̊-3 bound with high affinity (Kd = 40 ng/ml) to a single class of sites (Bmax = 8,000/cell) using NCI-H838 cells. 125I-αI̊-3 was internalized when exposed to NCI-H838 or H1299 cells at 37°C but not 4°C. αI̊-3 immunoprecipitated major 90 and 130 kD proteins. IGF-I stimulated and αI̊-3 inhibited the clonal growth of NCI-H1299 cells. αI̊-3 slowed the growth of NCI-H157 and H838 xenografts in nude mice. In a biodistribution study 125I-αI̊-3 was preferentially localized to the tumor as opposed to other organs. These data suggest that IGF-I may be a regulatory agent in NSCLC. © 1996 Wiley-Liss, Inc.This article is a US Government work and, as such, is in the public domain in the United States of America.
Zusätzliches Material:
6 Ill.
Materialart:
Digitale Medien
URL:
http://dx.doi.org/10.1002/jcb.240630522
Permalink
